FDA Breakthrough Designations Lead to Priority Reviews, Report Finds

A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more quickly, on top of frequently winning approval.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top